StemCyte, Inc. Releases Its 500th Cord Blood Stem Cell Shipment For Transplant

ARCADIA, Calif., April 16 /PRNewswire/ -- StemCyte, Inc., a privately-held stem cell therapy and cord blood company, with highly-accredited processing and storage facilities in both the U.S. and Taiwan, recently released its 500th cord blood stem cell shipment for transplant. This marks another milestone in the company's rapid growth as one of the world's leading providers of quality cord blood stem cell products. StemCyte has now provided cord blood stem cell shipments to over 130 transplant centers worldwide across 6 continents, with the number of shipments released for transplantation increasing rapidly. StemCyte's therapeutic products have been used for the treatment of over 40 diseases, including leukemias, lymphomas, immune diseases and genetic disorders.